Beta-blockade With Landiolol in Out-of-hospital Cardiac Arrest

Launched by MEDICAL UNIVERSITY OF VIENNA · Sep 22, 2022

Keywords

ClinConnect Summary

This clinical trial is examining the use of a medication called landiolol, a type of beta-blocker, to see how effective it is in treating patients who have had a cardiac arrest outside of the hospital. Specifically, the study focuses on patients who experience a condition known as refractory ventricular fibrillation, which is when the heart is not beating effectively and cannot be restored with standard treatments. Researchers want to find out if landiolol can help improve outcomes in these patients compared to a placebo, which is an inactive treatment.

To participate in this study, individuals must be at least 18 years old and have experienced an out-of-hospital cardiac arrest with three or more instances of shockable heart rhythms (these are rhythms that can be treated with electrical shocks). However, people over the age of 85, those with severe head injuries, or those who are allergic to landiolol or similar medications cannot take part. Participants will be closely monitored during the trial, and their health outcomes will be evaluated to understand the potential benefits of landiolol in this critical situation.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • OHCA , \>/=18 years of age
• • 3 or more shockable rhythms (VF or pVT) and last rhythm shockable
• Exclusion Criteria:
• • Age \> 85a
• • Severe head trauma or acute active bleeding
• • Known allergy or insensitivity to landiolol or another beta-blocker